IPSC-DERIVED MESENCHYMAL STROMAL CELLS EXPRESSING A NOVEL TNF INHIBITOR FOR THE TREATMENT OF RHEUMATOID ARTHRITIS
$487,407FY2025Defense Health AgencyDOD
Factor Bioscience Inc.
Investigators
View source on USAspending →IPSC-DERIVED MESENCHYMAL STROMAL CELLS EXPRESSING A NOVEL TNF INHIBITOR FOR THE TREATMENT OF RHEUMATOID ARTHRITIS · GrantIndex